Legend Biotech (NASDAQ:LEGN – Free Report) had its price objective lifted by Barclays from $93.00 to $94.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have an overweight rating on the stock. A number of other research analysts also recently issued reports on the company. Scotiabank began coverage on Legend […]
HC Wainwright restated their buy rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $87.00 price target on the stock. LEGN has been the subject of several other research reports. The Goldman Sachs Group began coverage on Legend Biotech […]
Legend Biotech (NASDAQ:LEGN – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.14, MarketWatch Earnings reports. The business had revenue of $96.00 million for the quarter, compared to analyst estimates of $97.25 million. The firm’s revenue was up […]
Legend Biotech (NASDAQ:LEGN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.14, MarketWatch Earnings reports. The company had revenue of $96.00 million during the quarter, compared to the consensus estimate of $97.25 million. The […]
Legend Biotech (NASDAQ:LEGN – Free Report) had its price objective increased by Barclays from $92.00 to $93.00 in a research note published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. Several other brokerages also recently issued reports on LEGN. Morgan Stanley upped their price objective on shares of Legend […]